In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a …
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price …
In a research note issued this morning, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …
In a report issued to investors this morning, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $32 …
In a research note published today, Maxim Group analyst Jason Kolbert assigned a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as …
In a research note published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as the …
In a research report released today to investors, H.C.
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and slightly raised his …
In a research note published today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $32 price target, in light …
In a research report issued today, H.C.